These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 39244723

  • 1. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, Tan JT, Qin J, Ng HY, Leung WK, Seto WK.
    Helicobacter; 2024; 29(5):e13133. PubMed ID: 39244723
    [Abstract] [Full Text] [Related]

  • 2. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
    Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, Siramolpiwat S, Eiamsitrakoon T, Gamnarai P, Wongcha-Um A, Yamaoka Y, Pawa KK, Vilaichone RK.
    Sci Rep; 2024 Apr 18; 14(1):8986. PubMed ID: 38637591
    [Abstract] [Full Text] [Related]

  • 3. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K.
    Gut; 2020 Jun 18; 69(6):1019-1026. PubMed ID: 31915235
    [Abstract] [Full Text] [Related]

  • 4. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024 Jun 18; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 5. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Hu Y, Huang XH, Zhou B, Liu ML, Liu YF, Yu T, Sun P, Tan BB, Hu Y, Cheng F, Pan XL, Hong JB, Shu X, Zhu Y, Lu NH.
    Helicobacter; 2024 Jun 18; 29(1):e13045. PubMed ID: 39191423
    [Abstract] [Full Text] [Related]

  • 6. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H.
    J Gastroenterol; 2020 Oct 18; 55(10):969-976. PubMed ID: 32666199
    [Abstract] [Full Text] [Related]

  • 7. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S, Deng Z, Cheung K, Lyu T, Chan P, Li Y, Ni L, Luo X, Li K.
    BMC Gastroenterol; 2023 Jul 07; 23(1):231. PubMed ID: 37420205
    [Abstract] [Full Text] [Related]

  • 8. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL, Wang JH, He XJ, Zhu YB, Lu LJ, Wang YJ, Wang ZW, Gao JG, Xu CF, Ma H, Luan SM, Li L, Chen Y.
    Am J Gastroenterol; 2024 Apr 01; 119(4):655-661. PubMed ID: 37975609
    [Abstract] [Full Text] [Related]

  • 9. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N, the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology.
    Antimicrob Agents Chemother; 2018 Sep 01; 62(9):. PubMed ID: 29914954
    [Abstract] [Full Text] [Related]

  • 10. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Ding YM, Zhang QM, Li RL, Han ZX, Zhao Q, Xu LD, Wang KY, Nan XP, Duan M, Zeng SY, Kong QZ, Wang H, Wu XQ, Zhang N, Li YQ, Zuo XL, Li YY.
    Helicobacter; 2024 Sep 01; 29(4):e13121. PubMed ID: 39097924
    [Abstract] [Full Text] [Related]

  • 11. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L, Zhang WF, Yang Z, Gao X, Zhang M, Li X, Zhang GX.
    Am J Gastroenterol; 2023 Apr 01; 118(4):627-634. PubMed ID: 36729890
    [Abstract] [Full Text] [Related]

  • 12. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z, Chen X, Sun DJ, Zhao WW, Kou L, Zheng WW, Hao JR, Gao FY.
    Medicine (Baltimore); 2024 Mar 08; 103(10):e37476. PubMed ID: 38457567
    [Abstract] [Full Text] [Related]

  • 13. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Gastroenterol Hepatol; 2023 Mar 08; 8(3):228-241. PubMed ID: 36549320
    [Abstract] [Full Text] [Related]

  • 14. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L, Wang Y, Ye J, Han Y, Lou G, Li Y, Yan H, Du Q.
    Helicobacter; 2023 Feb 08; 28(1):e12940. PubMed ID: 36458325
    [Abstract] [Full Text] [Related]

  • 15. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 16. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S.
    Intern Med; 2017 Nov 12; 56(11):1277-1285. PubMed ID: 28566587
    [Abstract] [Full Text] [Related]

  • 17. Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.
    Ding YM, Duan M, Han ZX, Song XH, Zhang FL, Wang Z, Ning Z, Zeng SY, Kong QZ, Zhang WL, Liu J, Wan M, Lin MJ, Lin BS, Nan XP, Wang H, Li YY, Zuo XL, Li YQ.
    Dig Dis Sci; 2024 Jul 12; 69(7):2540-2547. PubMed ID: 38700630
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S, Shen W, Liu Y, Dong Q, Shi Y.
    Chin Med J (Engl); 2023 Jul 20; 136(14):1690-1698. PubMed ID: 37469024
    [Abstract] [Full Text] [Related]

  • 19. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J, Mei H, Su NY, Sun WJ, Zhang DK, Fan LL, He P, Pan J, Wang XW, Zou PY, Liu YX, Guo Y, Lan CH.
    Helicobacter; 2023 Aug 20; 28(4):e12970. PubMed ID: 37160689
    [Abstract] [Full Text] [Related]

  • 20. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG.
    Aliment Pharmacol Ther; 2015 Apr 20; 41(8):768-75. PubMed ID: 25703120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.